Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO

Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma

Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar settings – per trial results to be presented in an oral session at ASCO

Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations

ACADIA Pharma

Agios Pharmaceuticals

Amgen

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

BioMarin Pharmaceutical

CareDx

Exact Sciences

Exelixis

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Ionis Pharma

IQVIA Hlds

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Seagen

Teladoc

TG Therapeutics

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo

Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine

Sanofi

Dupixent ® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

$75,000 Top Award Goes to 17 -year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens TARRYTOWN, N.Y. and WASHINGTON, May 19, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.  and Society for Science  (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global pre-college science and engineering competition, for a project that explored planets that orbit very close around their suns.

High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens $75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens

High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023

Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent ® (alirocumab)

Regeneron Applauds Supreme Court's Unanimous Opinion Striking Down Amgen's PCSK9 Patent Claims and Supporting Scientific Innovation

United Therapeutics

Much of what the FTC attacks isn't anticompetitive, it's competitive. The most cynical anticompetitive acts coopt state mechanisms.

Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC

AMN Healthcare Services

Patrick Industries

BRP Inc

Globant

Nexstar Media Group

Winnebago

Although recent headwinds like stubbornly high inflation and the banking sector crisis knocked the wind out of several publicly traded enterprises, a select number of hardened survivors potentially represent growth stocks to buy now. Using Gurufocus, all the companies below feature (on a per-share basis) five-year and ten-year growth rates of 20% and 15%, respectively.

The 7 Growth Stocks You Need to Own Now for Maximum Returns

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 9:30 AM ET Company Participants Aris Baras – Senior Vice President, Regeneron Genetics Center Christos Kyratsous – Senior Vice President-Research Ryan Crowe – Vice President-Investor Relations Conference Call Participants Brian Abrahams – RBC Capital Markets Brian Abrahams Again for being here I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. Our next feature company is Regeneron.

Regeneron Pharmaceuticals, Inc. (REGN) 2023 RBC Capital Markets Global Healthcare Conference Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bank of America Global Healthcare Conference Call May 9, 2023 4:40 PM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP, Finance & CFO Conference Call Participants Geoff Meacham - Bank of America Merrill Lynch Geoff Meacham Welcome to the afternoon of the first day of the BofA Healthcare Conference. So my name is Geoff Meacham.

Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call Transcript

Vertex has no shortage of pipeline candidates in addition to its wildly successful cystic fibrosis franchise. Regeneron faces competition for one of its key products, but it also may see a major approval.

2 Cathie Wood Stocks That Can Get You Through Any Recession

Regeneron Pharmaceuticals Inc. NASDAQ: REGN gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

Regeneron Pharmaceuticals posted overall positive 2023 Q1 results today. Even so, investors are concerned about the competitive positioning of the drugmaker's blockbuster eye-care treatment.

Why Regeneron Pharmaceuticals Stock Is Tanking Today

While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 Earnings

Regeneron (REGN) came out with quarterly earnings of $10.09 per share, beating the Zacks Consensus Estimate of $9.25 per share. This compares to earnings of $11.49 per share a year ago.

Regeneron (REGN) Q1 Earnings and Revenues Top Estimates

Regeneron Pharmaceuticals beat first-quarter sales and profit calls, but Eylea revenue came up short and REGN stock tumbled. The post Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker appeared first on Investor's Business Daily.

Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker

Regeneron Pharmaceuticals Inc. ‘s stock REGN, +0.59% slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023. The Tarrytown, N.Y.

Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower

TARRYTOWN, N.Y., May 04, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2023 and provided a business update.

Regeneron Reports First Quarter 2023 Financial and Operating Results

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Regeneron (REGN)

Ligand Pharmaceuticals

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Ligand Pharmaceuticals (LGND) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?

News for Regeneron Pharmaceuticals Stock (REGN)